REGN
Regeneron Pharmaceuticals, Inc.
Platform & Compounding FCF
B-
62.7 / 100 composite
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
-
5yr Avg ROIC
14.5%
-
Operating Margin Trend
-7.76 pp/yr
-
5yr Avg ROE
16.2%
-
5yr Share-Count CAGR
-0.8%
-
5yr Revenue CAGR
-2.8%
-
5yr EPS CAGR
-12.9%
-
Revenue-Growth Years (5)
4/5
-
5yr FCF Margin
31.8%
-
5yr FCF/NI Conversion
0.90x
-
Net Debt / EBITDA
-1.01x
-
Interest Coverage (EBIT/Int)
120.42x
-
Altman Z-Score
6.60
Stability
Weight: 5%
C-
44
-
EPS Volatility (σ/μ)
0.67
-
Piotroski F-Score
5
-
Negative-Revenue Years (5)
1/5
4 of 4 gurus held; 2 added; 2 trimmed.
- Holders
- 4
- Avg Δ position
-
+3931.7%
- New buys
- 0
- Full exits
- 0